Enliven Therapeutics, Inc. (ELVN) Institutional Ownership

Ownership Summary

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has 126 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 100.4% of Enliven Therapeutics's outstanding shares in December 2025, up from 95.1% in September 2025.
• They increased total shares held in Enliven Therapeutics by 10.6% from last quarter, and the number of investors in ELVN increased 10.53% annually.
• During the quarter, 64 of these 126 funds increased positions in ELVN, 45 reduced exposure, and 17 held steady.
• Altogether, these fund groups held 62.32Mn shares in ELVN by December 2025, up by 5.97Mn shares quarter on quarter, and up 12.46Mn shares year over year.
• As of December 31, 2025, ORBIMED ADVISORS LLC held the largest stake in Enliven Therapeutics with 7.96Mn shares, accounting for 12.82% of total shares outstanding.
• The most significant purchases of ELVN for the quarter ending December 2025 came from Vestal Point Capital, LP (2.67Mn), Soleus Capital Management, L.P. (1.02Mn), Point72 Asset Management, L.P. (464.19K), Spruce Street Capital LP (446.08K), Polar Capital Holdings Plc (418.67K).
• Leading sellers of Enliven Therapeutics shares for the quarter ending December 2025 were Franklin Resources Inc (410.07K), Blackstone Inc. (365.65K), HighVista Strategies LLC (176.6K), Candriam S.C.A. (156.33K), Janus Henderson Group Plc (121.86K).
• Business Quant data shows the 10 biggest positions in Enliven Therapeutics as of December 2025 are held by ORBIMED ADVISORS LLC (7.96Mn), FMR LLC (7.11Mn), Commodore Capital LP (4.69Mn), Vestal Point Capital, LP (3.83Mn), Fairmount Funds Management LLC (3.71Mn), BlackRock, Inc. (3.61Mn), Polar Capital Holdings Plc (3.51Mn), VR Adviser, LLC (3.23Mn), VANGUARD GROUP INC (2.8Mn), Janus Henderson Group Plc (1.67Mn).